Sight Sciences, Inc. (SGHT)
NasdaqGS · USD · Healthcare · Medical Devices
$9.02 (+0.33%) as of
Key statistics
- Market cap
- 496.89M
- Forward P/E
- -22.54
- EPS (TTM)
- -0.56
- Dividend yield
- 0.00%
- 52-week range
- 3.38 – 9.71
- Beta
- 2.45
- Revenue (TTM)
- 83.38M
- Profit margin
- -35.69%
- Analyst target
- $10.17
- Volume
- 267.80k
About Sight Sciences, Inc.
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Menlo Park, CA, United States
- Employees
- 186
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.